94 related articles for article (PubMed ID: 25503122)
1. Expression of MSH2 and MSH6 on a tissue microarray in patients with osteosarcoma.
Jentzsch T; Robl B; Husmann M; Bode-Lesniewska B; Fuchs B
Anticancer Res; 2014 Dec; 34(12):6961-72. PubMed ID: 25503122
[TBL] [Abstract][Full Text] [Related]
2. Worse prognosis of osteosarcoma patients expressing IGF-1 on a tissue microarray.
Jentzsch T; Robl B; Husmann M; Bode-Lesniewska B; Fuchs B
Anticancer Res; 2014 Aug; 34(8):3881-9. PubMed ID: 25075009
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant therapy induces loss of MSH6 expression in colorectal carcinoma.
Bao F; Panarelli NC; Rennert H; Sherr DL; Yantiss RK
Am J Surg Pathol; 2010 Dec; 34(12):1798-804. PubMed ID: 21107085
[TBL] [Abstract][Full Text] [Related]
5. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
[TBL] [Abstract][Full Text] [Related]
6. Treatment algorithm for locally recurrent osteosarcoma based on local disease-free interval and the presence of lung metastasis.
Nathan SS; Gorlick R; Bukata S; Chou A; Morris CD; Boland PJ; Huvos AG; Meyers PA; Healey JH
Cancer; 2006 Oct; 107(7):1607-16. PubMed ID: 16933325
[TBL] [Abstract][Full Text] [Related]
7. Metastatic osteosarcoma.
Daw NC; Billups CA; Rodriguez-Galindo C; McCarville MB; Rao BN; Cain AM; Jenkins JJ; Neel MD; Meyer WH
Cancer; 2006 Jan; 106(2):403-12. PubMed ID: 16353204
[TBL] [Abstract][Full Text] [Related]
8. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience.
Mialou V; Philip T; Kalifa C; Perol D; Gentet JC; Marec-Berard P; Pacquement H; Chastagner P; Defaschelles AS; Hartmann O
Cancer; 2005 Sep; 104(5):1100-9. PubMed ID: 16015627
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of MSH6 gene silencing in combination with cisplatin on cell proliferation of human osteosarcoma cell line MG63.
Liu HC; Zeng J; Zhang B; Liu XQ; Dai M
J Cell Physiol; 2019 Jun; 234(6):9358-9369. PubMed ID: 30456894
[TBL] [Abstract][Full Text] [Related]
10. Expression and prognostic relevance of centromere protein A in primary osteosarcoma.
Gu XM; Fu J; Feng XJ; Huang X; Wang SM; Chen XF; Zhu MH; Zhang SH
Pathol Res Pract; 2014 Apr; 210(4):228-33. PubMed ID: 24440098
[TBL] [Abstract][Full Text] [Related]
11. CSE1L interaction with MSH6 promotes osteosarcoma progression and predicts poor patient survival.
Cheng DD; Lin HC; Li SJ; Yao M; Yang QC; Fan CY
Sci Rep; 2017 Apr; 7():46238. PubMed ID: 28387323
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis.
Kaya M; Wada T; Akatsuka T; Kawaguchi S; Nagoya S; Shindoh M; Higashino F; Mezawa F; Okada F; Ishii S
Clin Cancer Res; 2000 Feb; 6(2):572-7. PubMed ID: 10690541
[TBL] [Abstract][Full Text] [Related]
13. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS).
Kempf-Bielack B; Bielack SS; Jürgens H; Branscheid D; Berdel WE; Exner GU; Göbel U; Helmke K; Jundt G; Kabisch H; Kevric M; Klingebiel T; Kotz R; Maas R; Schwarz R; Semik M; Treuner J; Zoubek A; Winkler K
J Clin Oncol; 2005 Jan; 23(3):559-68. PubMed ID: 15659502
[TBL] [Abstract][Full Text] [Related]
14. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract][Full Text] [Related]
15. Examination of the cutoff value of postchemotherapy increase in tumor volume as a predictor of subsequent oncologic events in stage IIB osteosarcoma.
Jeon DG; Kong CB; Cho WH; Song WS; Cho SH; Choi SW; Lee SY
J Surg Oncol; 2014 Mar; 109(3):275-9. PubMed ID: 24243222
[TBL] [Abstract][Full Text] [Related]
16. pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.
Thanapprapasr K; Nartthanarung A; Thanapprapasr D; Jinawath A
PLoS One; 2017; 12(8):e0182989. PubMed ID: 28846700
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
Bacci G; Longhi A; Versari M; Mercuri M; Briccoli A; Picci P
Cancer; 2006 Mar; 106(5):1154-61. PubMed ID: 16421923
[TBL] [Abstract][Full Text] [Related]
18. Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients.
Bacci G; Longhi A; Cesari M; Versari M; Bertoni F
Cancer; 2006 Jun; 106(12):2701-6. PubMed ID: 16691623
[TBL] [Abstract][Full Text] [Related]
19. P16 expression predicts necrotic response among patients with osteosarcoma receiving neoadjuvant chemotherapy.
Borys D; Canter RJ; Hoch B; Martinez SR; Tamurian RM; Murphy B; Bishop JW; Horvai A
Hum Pathol; 2012 Nov; 43(11):1948-54. PubMed ID: 22578565
[TBL] [Abstract][Full Text] [Related]
20. Elevated expression of AKT2 correlates with disease severity and poor prognosis in human osteosarcoma.
Zhu Y; Zhou J; Ji Y; Yu B
Mol Med Rep; 2014 Aug; 10(2):737-42. PubMed ID: 24919955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
